Oculis Holding AG

OCS Healthcare Biotechnology

Oculis Holding AG’s revenue for fiscal 2025 (year ended December 2025) was $1.4 million, up 85.7% from fiscal 2024. In the quarter to June 2026, revenue grew 24.0%, EPS grew 66.1%, free cash flow fell 10.4% and total debt rose 159.8%, each against the same quarter a year earlier.

7.29 0.11 −1.49%
Market cap
$456.8M
P/E
0.0×
Fwd P/E
−5.1×
Dividend yield
—
F-score
4/9
Altman Z
10.51
Beneish M
n/a
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Piotroski F-Score
4 3 3 — —
P/E ratio
0.00 0.00 0.00 0.00 107.67
P/S ratio
720.95 881.46 0.00 0.00 0.00
Altman Z-Score
10.51 3.01 4.86 (6.55) (1.45)
Altman Z″-Score (non-manufacturers)
2.59 (6.88) (0.97) (14.33) (1.17)
P/FCF ratio
0.00 0.00 0.00 0.00 0.00
P/Operating CF
(57.88) (62.23) (28.44) (1.59) (10.51)
P/B ratio
4.41 8.24 3.36 0.00 0.00
EV/Sales
545.04 739.37 0.00 0.00 0.00
EV/EBITDA
0.00 0.00 0.00 0.00 0.00
EV/FCF
(9.65) (10.62) (3.63) (2.80) (14.97)
Current Ratio
5.96 2.37 5.29 1.97 11.81
Net Debt/EBITDA
2.60 1.34 1.13 (3.20) (5.16)
Debt/Equity
0.01 0.01 0.01 (1.25) (1.87)
ROE
(74.65%) (103.79%) (11,509.96%) 47.88% 0.00%
ROA
(56.67%) (73.79%) (119.02%) (79.25%) 0.00%
ROIC
0.00% 0.00% (1,747.97%) (391.93%) (120.78%)
Return on Tangible Assets
(54.17%) (140.51%) (108.01%) (322.43%) (41.83%)
Average Days of Receivables
0.00 0.00 0.00 0.00 0.00
Earnings Yield
(11.37%) (13.59%) (103.46%) (103.29%) 0.93%
Free Cash Flow Yield
(7.83%) (7.90%) (19.39%) (152.83%) (9.82%)
Free Cash Flow per Share
(1.56) (1.34) (2.01) (10.03) (5.46)
Book value per Share
4.53 2.06 3.49 (34.35) (24.01)
Free Cash Flow
(81.70) (54.22) (60.03) (29.99) (15.16)
EV/EBIT
0.00 0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates